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Introduction
Aromatase 2004 was held in Edinburgh, Scotland on 6–8
September 2004. More than 200 delegates and 30
invited speakers formed a faculty drawn from 23 countries.
The programme embraced basic science, translational
research and clinical practice. Topics included pheno-
types of oestrogen deprivation and excess, regulation and
role of aromatase, effects and end-points of aromatase
inhibitors (AIs), AI use for breast cancer therapy and other
clinical conditions, long-term effects, and resistance to
AIs, from which the following perspective is distilled.
Phenotypes of oestrogen deprivation and
excess
Two models of oestrogen insufficiency were described:
aromatase knockout (ArKO) and estrogen receptor
knockout (ERKO) mice.
The phenotype of ArKO mice, as described by Evan
Simpson, included a metabolic syndrome with increased
intra-abdominal adipose tissue accumulation, hyper-
insulinaemia, hyperleptinaemia, decreased physical activity
and decreased glucose utilization. Males developed
striking sexually dimorphic hepatic steatosis and neuronal
loss in some hypothalamic areas. This ArKO mouse
phenotype mirrored clinical features in a man with
aromatase deficiency who developed type 2 diabetes,
truncal obesity, acantosis nigricans and hepatic steatosis.
Describing the phenotype of ERKO mice, Ken Korach
concentrated on the reproductive system and on hormonal
carcinogenesis. He distinguished between mice knocked
out for estrogen receptor (ER)-α and those knocked out
for ER-β. Mammary gland morphology was severally
disrupted in α ERKO females, whereas normal develop-
ment occurred in the β ERKO mice. α ERKO mice were
infertile, whereas β ERKO animals were subfertile.
Additionally, ER-α appeared to be more influential in
hormonal carcinogenesis than did ER-β.
Raj Tekmal studied the impact of oestrogen excess on
mammary gland development in aromatase over-
expressing transgenic mice. It was sufficient to induce
neoplastic changes and may increase cancer incidence –
effects abrogated by AIs.
Regulation of aromatase
The human aromatase gene (CYP19) is regulated by
tissue specific promoters, and alternative splicing of the
first exon provides tissue-specific regulation.
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Abstract
Aromatase is the key enzyme involved in oestrogen biosynthesis. Oestrogens not only influence normal
development and function but are also implicated in the aetiology and progression of many diseases.
Over recent years rational drug design programmes have led to the development of agents that
specifically and potently inhibit aromatase. The multidisciplinary international symposium Aromatase
2004 provided a forum in which basic scientists, translational researchers and practising clinicians
reviewed latest results, exchanged opinions, and defined future needs for the regulation of oestrogen
biosynthesis and the use of aromatase inhibitors.
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Control of aromatase in the breast was of particular
interest. Enhanced oestrogen production in breast
cancers could result from promoter switching induced by
autocrine and paracrine factors. These mechanisms were
discussed by Shiuan Chen, who characterized
transcription factors enhancing aromatase expression at
promoters I.3 and II in breast cancers, and by Colin Clyne,
who discussed the role of prostaglandin E2 and liver
receptor homologue-1 in the interaction between tumour
and surrounding adipose tissue.
Describing novel mechanisms for regulation of aromatase
transcription, Carole Mendelson emphasized the role of
hypoxia in placental expression. The regulation of
aromatase in brain, endometriosis/uterine fibroids and
testis was reviewed by Nobuhiro Harada, Serdar Bulun
and Serge Carreau. Bonnie King characterized macro-
phages in lavage fluid from breast ducts as being
aromatase-positive by immunocytochemistry.
Investigational approaches
A new monoclonal antibody with which to measure
aromatase immunohistochemically in breast cancer was
described by Hiro Sasano. Standardization of both
staining and scoring was emphasized. The most promising
antibody (677) localized aromatase to different tissue
components, but there were positive correlations between
immunohistochemical staining of cancer cells and
aromatase activity and mRNA expression.
The relative merits of models used to monitor the effects
of AIs were reviewed by Angela Brodie. In the model of
xenografts of MCF-7 cells (transfected with the aromatase
gene) in nude mice, the combination of anastrozole and
tamoxifen was no better than tamoxifen alone and inferior
to single agent anastrozole in controlling tumour growth –
an effect that was recently confirmed in the clinical setting.
More recent results in this model suggest that addition of
fulvestrant to letrozole may delay hormone resistance.
The effects and end-points of aromatase
inhibitors
The endocrinology of the ‘third-generation’ AIs anastrozole,
letrozole and exemestane was described by Jurgen Geisler
in terms of effects on total aromatase inhibition and
suppression of plasma oestrogen levels. All three com-
pounds inhibited aromatase by 97–99% in vivo and sup-
pressed the major circulating oestrogen in postmeno-
pausal women, namely oestrone sulphate, by up to 99%.
Using neoadjuvant treatment protocols, Bill Miller showed
that anastrozole, letrozole and exemestane produced
marked molecular and pathological changes in ER-rich
breast cancers. Changes in tumour morphology occurred
in over 60%. Profound reduction in expression of a
proliferation marker (MIB-1) and progesterone receptors
were seen in about 90%. Microarray RNA analysis
subdivided tumours into distinct groups according to
molecular changes, although the relationship to
clinical/pathology response remains to be determined.
The clinical end-points used to establish disease efficacy
in breast cancer trials were reviewed by Matt Ellis. He
identified the need to develop more robust criteria to
determine tumour response to therapy in individual
patients and suggested that a combination of clinical,
radiological, histopathology and multiple biomarkers be
used.
A surgical perspective was provided by Mike Dixon.
Results from neoadjuvant trials show that AIs have
advantages in comparison with tamoxifen. More patients
with locally advanced breast cancer become operable,
more have breast conservation surgery with complete
excision, and there are lower local recurrence rates.
Breast cancer therapy
Novel AIs are having a major impact on breast cancer
therapy. Jim Ingle reviewed use in patients with advanced
disease. Anastrozole and letrozole were superior to
tamoxifen in the first-line setting, and in the second-line
setting they were superior to megestrol acetate in terms of
time to progression, overall response, clinical benefit and
toxicity profile. (Exemestane exhibited a similar pattern over
tamoxifen.) Although differences may exist between AIs,
there are only limited trial results directly comparing the
drugs in advanced disease, and there is no level 1 evidence
to distinguish between them. Clinical trials are needed to
determine optimal sequencing strategies and use of AIs in
premenopausal women, either as monotherapy or in
combination with suppression of ovarian function.
Nicholas Robert reviewed the three major trials in which
AIs were given in the adjuvant setting for early stage
breast cancer. In the ATAC (Arimidex, Tamoxifen Alone or
in Combination) trial, patients were randomly assigned to
receive anastrozole or tamoxifen as initial therapy. In the
IES (Intergroup Exemestane Study) trial, patients receiving
tamoxifen for 2–3 years were randomly assigned to
continue on tamoxifen or swap to exemestane. In the third
trial, the MA17 trial, women receiving 5 years of tamoxifen
were randomly assigned to receive letrozole or placebo. In
all, AIs produced superior clinical results to the control
arms. Important questions still need to be addressed.
What is the optimal time to introduce AIs (initially or after
2–3 years or 5 years of treatment with tamoxifen)? What is
the optimal duration of AIs? Is a particular AI superior in
particular settings? Finally, how are patients best selected
for treatment?
As discussed by Ian Smith, the primary clinical benefit of
neoadjuvant therapy is down-sizing of the tumour. Evidenceof clinical response might also help in planning adjuvant
management. Research benefits of neoadjuvant therapy in
identifying mechanisms of response and resistance to
treatment and associated predictive markers was
emphasized. Two large clinical trials demonstrated that
letrozole and anastrozole achieved higher rates of clinical
response and conversion to breast conservation than did
tamoxifen in large primary tumours; both AIs were more
effective than tamoxifen against HER-2 positive cancers.
Clinical trials with AIs were summarized by Jack Cuzick.
Third-generation inhibitors were at least as effective as
tamoxifen in advanced disease and in the adjuvant setting,
and had fewer side effects. Effects on new contralateral
tumours were greater than those on recurrent diseases.
Important results are expected from several trials due to
report in the near future.
Robert Brueggeiemer provided the evidence for co-
regulating aromatase and cyclo-oxygenase as a
therapeutic option for patients with hormone-dependent
breast cancer. Details were given of an ongoing
neoadjuvant trial of exemestane and celecoxib.
Per Lonning considered social economical issues. He
concluded that clinical benefits of AIs in adjuvant therapy
were achieved at acceptable cost. In the setting of
prevention the appropriate calculations were complicated
by difficulties in identifying high-risk groups; appropriate
cost studies were deemed to be mandatory and to require
careful consideration.
Premenopausal women
Effects and potential applications of AIs in premenopausal
women were summarized by Dominique de Ziegler. AIs
interfere with ovarian oestrogen production and elevate
gonadotrophins. Consequently, follicular growth is
stimulated in the ovary. AIs therefore offer an effective
method for inducing ovulation and a treatment for
infertility. Other applications in premenopausal women
were for endometriosis and uterine fibroids, or even to
achieve medical abortion.
Long-term effects of aromatase inhibitors
AIs are being considered as cancer preventatives and in
other settings for which long-term administration would be
necessary. It is therefore important that the effects of
chronic administration are evaluated, but results from
primary prevention trials are still awaited.
Tony Howell focused on ‘vascular’ events and cognitive
function. He concluded that, to date, the third-generation
AIs had no significant effects on cardiovascular,
cerebrovascular and thromboembolic events; influences
on cognitive function, although thought detrimental, were
unassessable.
Effects on bone were reviewed by Richard Eastell. Data
from large trials in breast cancer patients suggest that AIs
may be associated with increased risk for fracture or
oesteoporosis. Comparisons have often been with
tamoxifen, which itself may decrease bone turnover and
change bone mineral density. Important questions remain
unanswered. Is bone loss with AIs progressive? Are
effects similar with all inhibitors? What are the risk factors
for fractures? Can changes be prevented with agents
such as bisphosphonates?
Long-term effects on the endometrium were considered
by Sean Duffy. In general, AIs have a better
gynaecological profile than tamoxifen. Results from the
ATAC trial indicate that anastrozole suppresses the
endometrium. Endometrial pathology including cancer was
lower among patients receiving anastrozole and lower
than expected rates in age-matched populations.
Resistance to aromatase inhibitors
Mitch Dowsett reviewed the mechanisms of resistance to
AIs, which may be subdivided into de novo/intrinsic and
acquired resistance. Absence of tumour ERs was a key
marker of de novo resistance in breast cancer but, in ER-
positive tumours, progesterone receptor negativity and
over-expression of type I growth factor receptors were
also influential. Acquired resistance could result from
several mechanism, but hypersensitivity to oestrogen
mediated through over-expression of other signalling
systems, such as HER2, was highlighted.
In his plenary lecture, Richard Santen showed how
crosstalk between ERs and growth factors through
‘nongenomic’ effects could lead to adaptive hypersensitivity
and to resistance to AIs in oestrogen-deprived cells.
Blocking key molecules on the pathways (mitogen-activated
protein kinase, phosphatidylinositide-3 kinase and
mammalian target of rapamycin [mTOR]) with agents such
as farnesylthiosalycylic acid may extend the efficacy of AIs.
Stephen Johnston further considered the combination of
endocrine agent with inhibitor of signal transduction. He
presented the rationale for employing inhibitors of tyrosine
kinase and farnasyl transduction and mTOR antagonists
with AIs and pure anti-oestrogens. Randomized phase II/III
clinical trials are in progress to test these strategies.
Kent Osborne also presented compelling results
indicating that the combination of a variety of agents that
inhibit epidermal growth factor receptor family signalling
plus tamoxifen could completely abolish the growth of
hormone sensitive tumours. He confirmed that AIs were
effective in blocking ER genomic and nongenomic
pathways, and that growth factor pathways contributed to
resistance to AIs. The plea was made for future clinical
trials to be accompanied by molecular profiling.
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The explosion of activity surrounding aromatase and its
inhibitors was reflected in the presentations at Aromatase
2004. It was clear that, although many issues had been
resolved, many questions remained to be answered.
These will be challenges for the next Aromatase
Symposium, which will be held in the USA in 2006.
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